Menu

Blog posts October 2022

Quorum Software Showcases Quorum Energy Suite to Middle East Energy Market at ADIPEC 2022

Global oil and gas software leader exhibiting at booth #13375

(BUSINESS WIRE) -- Quorum Software (Quorum), a global software leader dedicated to the energy industry, announced today it will be attending the Abu Dhabi International Petroleum and Exhibition Conference (ADIPEC) 2022 from 31 October to 3 November. ADIPEC is one of the world’s largest oil and gas events, where international leaders convene in the Middle East to engage and identify opportunities in an evolving energy landscape. At booth #13375, Quorum solution experts will provide software demonstrations and exhibit key applications within the company’s Quorum Energy Suite (QES) including Energy Components, FLOWCAL, and Planning Space.

“In a rapidly changing energy market, companies need reliable, cloud-first solutions that deliver fast, accurate, and decision-ready data to power their critical operations and support their energy transition objectives,” said Paul Langenbahn, President and CEO at Quorum Software. “Quorum remains committed to being the go-to partner and driver of continuous and connected value for the Middle East and around the world. We look forward to attending ADIPEC to showcase the power of the Quorum Energy Suite to optimize business performance across the energy value chain.”

Quorum will be hosting the following series of “Tech Talks” at booth #13375:

31 Oct., 14.00 - 14.30: “Powering the Business of Energy Transition: Carbon Capture Storage, Emissions Measurement, Hydrogen” with Eli Ottesen, Director, Solution Architect and James Lang, Vice President, Middle East.

1 Nov., 14.00 - 14.30: “Energy Components: Optimizing and Supporting the LNG Value Chain” with Eirik Magelssen, Solution Architect Director.

2 Nov., 14.00 - 14.30: “Energy Components: Tracking Your Hydrocarbons from Exploration to Distribution Worldwide” with Eli Ottesen, Director, Solution Architect.

3 Nov., 14.00 - 14.30: “Streamlining the Measurement Process and Increasing Operational Efficiency with FLOWCAL” with James Lang, Vice President, Middle East.

To learn more about Quorum, please visit www.quorumsoftware.com. To schedule a meeting with one of our experts on-site at ADIPEC, please visit https://info.qbsol.com/adipec-2022.

About Quorum Software

Quorum Software is a leading provider of energy software worldwide, serving more than 1,800 customers across the entire energy value chain in 55 countries. Quorum’s solutions power growth and profitability for energy businesses by connecting people, workflows, and systems with decision-ready data. Twenty years ago, we delivered the industry’s first software for gas plant accountants, and today our solutions streamline business operations with industry forward data standards and integrations. The global energy industry trusts Quorum’s experts and applications to successfully navigate the energy transition while delivering value today and into the future. For more information, visit quorumsoftware.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005802/en/


Permalink
https://www.aetoswire.com/en/news/2610202228013
Contacts
Media
Lauren Force
PAN Communications
Quorum@pancomm.com

Go Back

Space Innovation for Earth with the SeRANIS Mission

BETZDORF, Luxembourg & NEUBIBERG, Germany - Wednesday, 26. October 2022

LuxSpace and Universität der Bundeswehr München (UniBw M) sign contract for SeRANIS mission with Triton-X platform for smallsats

(BUSINESS WIRE) -- LuxSpace, a subsidiary of space and technology group OHB SE, and the Universität der Bundeswehr München (University of German Armed Forces Munich) just signed a contract for the dtec.bw SeRANIS (Seamless Radio Access Network for Internet of Space) small satellite mission. This UniBw M mission provides the world's first publicly accessible multifunctional experimental laboratory in orbit and will use the LuxSpace built Triton-X Heavy platform.

SeRANIS is a small satellite mission with 15 experiments to explore key future technologies in various fields, including future 6G mobile communication systems, laser communication and Internet of Things.

“With the goal to create a multi-functional experimental laboratory on one satellite, the SeRANIS mission is unique and substantially different from traditional “CubeSat” based research approaches. Due to the high complexity of this mission, a reliable and agile platform is needed. The Triton-X Heavy platform prevailed in our call for tenders,” said SeRANIS project leader, Prof. Dr. Andreas Knopp, Professor Space Research Center, Universität der Bundeswehr München. “The SeRANIS mission has two aims: Paving the way for the Bundeswehr’s access to new capabilities in Low Earth Orbit and offering an orbital lab for the German research community.”

Edgar Milic, CEO of LuxSpace said “LuxSpace is proud and enthusiastic to be part of the SeRANIS mission with our high performance and scalable Triton-X platform for smallsats. The variety of innovative technologies and payloads aboard SeRANIS is an ideal fit for our multi-mission platform developed in Light/Medium/Heavy mass classes for up to 250 kg satellites".

About UniBw and dtec.bw
The Universität der Bundeswehr München (www.unibw.de) serves the academic training of military and civilian students. SeRANIS is a research project funded by dtec.bw – Digitalization and Technology Research Center of the Bundeswehr. More on www.dtecbw.de and www.seranis.de

About LuxSpace
LuxSpace was established in Luxembourg in 2004 as a subsidiary of OHB SE and is an integrated provider of small satellites and space-based applications and services. The company can look back on seven successfully launched space systems, including the Triton-2/ESAIL satellite launched in September 2020, and has over 16 years of experience in data applications with a particular focus on the maritime sector and Earth observation. More on www.luxspace.lu

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005550/en/


Permalink
https://www.aetoswire.com/en/news/2610202228038
Contacts
Media LuxSpace:
Florio Dalla Vedova
Marketing Responsible
dallavedova@luxspace.lu

Media UniBw:
Michael Brauns
Press Spokesman
michael.brauns@unibw.de

 

Go Back

New Study from Egon Zehnder Finds Boards Need Four Key Ingredients to Become Stewards of Sustainability

ZURICH - Wednesday, 26. October 2022 

Survey of the 100 largest companies globally reveals that while 80 percent of boards now have sustainability committees, crucial elements are missing to turn intention into action

(BUSINESS WIRE) -- A report released today by Egon Zehnder, the world’s preeminent leadership advisory firm, has found that while boards are prioritizing sustainability, there is much room for improvement – and getting the right composition, culture, mindset and skills are key for driving environmental, social and governance (ESG) agendas.

The study, “Boards: Stepping Up as Stewards of Sustainability,” which draws on insights from The 2022 Sustainability Board Report, found that just over a quarter of the directors were members of a relevant committee and 45 percent of committees were assessed to be engaged with environmental, social and governance (ESG) issues.

Ahead of COP 27, the study charts a path for boards, finding that diverse boards with a culture of courage, a divergence of skills, and a flexible mindset can extend this focus to put ESG at the core of how they do business.

The report makes four recommendations that would help companies increase their sustainability engagement:

Move ESG to the core of board activities. This requires a board, guided by the chair, to embrace a flexible approach, knowing that plans will change as the journey evolves.

Embrace ESG board education and self-reflection. While training sessions and expert consultations are useful tools at the beginning of the sustainability journey, board members need to take it upon themselves to be curious and stay on top of relevant ESG issues.

Ensure diversity of age and gender to challenge mindsets. The survey found that diversified boards tend to function better than homogenous entities. While there has been improvement in the gender mix, companies would benefit from adding younger people to their boards, to gain a wide range of perspectives.

Shake up culture and board dynamics. Being cognizant of the potential of diverse, courageous, and visionary boards is an important step on the path to sustainability. Boards should challenge current practices and brainstorm new ways of operating with ESG at the core.

“There is a bravery in not accepting incrementalism,” says Jill Ader, chair of Egon Zehnder. “Give boards the option to go far, and then the option to go further, and they’ll likely take the further option.”

For more information on Egon Zehnder’s “Boards: Stepping Up as Stewards of Sustainability,” visit https://www.egonzehnder.com/stewards-of-sustainability.

About Egon Zehnder

Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose. Our 560 consultants across 63 offices and 37 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries and functions to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership.

For more information, visit egonzehnder.com and follow us on LinkedIn and Twitter.

About TSBR

The Sustainability Board Report (TSBR) is an independent not-for-profit project. We aim to showcase different dimensions of sustainable leadership and corporate governance. By developing best practice and thought leadership, our reports help individual leaders, organisations and investors to understand the changing landscape of environmental, social and governance (ESG) preparedness, consciousness and competence.

We collabo­rate with business leaders, non-executive directors, board advisors and academia to create meaningful, actionable, and potent narratives. TSBR also releases an annual report on ESG preparedness of boards of directors of the world’s largest publicly listed companies. Our work has featured in leading business and academic publications and is considered a trusted resource for sustainable leadership and governance insights.

To learn more please visit www.boardreport.org.

Deeper Dive: The Study’s Key Findings

Most boards are aware of the sustainability challenge and are at different stages of engaging with their stewardship roles on driving ESG integration. They do not, however, have the skills and knowledge to fully integrate sustainability into the boards’ activities and responsibilities. Making step changes in how the board functions requires vision and courage.

The findings highlight a link between diversity and ESG engagement, and notably that women and younger board members have a positive effect on corporate sustainability. A sustainability-engaged board also requires the right mix of individuals.

Four actions are identified to increase board maturity on sustainability. These are moving ESG to the core of board activities, rather than being a sideline activity; developing board members through education and exposure; challenging mindsets through increasing diversity; and shaking up board dynamics and culture through ensuring the right blend of individuals on the board.

Individuals differ in terms of their understanding of and engagement with sustainability. Board members may include those with an individual interest or passion in sustainability but are unlikely to drive action; those having some interest in individual sustainability topics or solutions; those who will drive change in the organization; and as those engaging with sustainability as a systemic challenge. Boards increasingly need those further down this “span of influence” to meaningfully integrate sustainability into their activities and decisions. Egon Zehnder‘s stewardship assessment framework can help identify ways in which individuals can bring value to the board.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005071/en/


Permalink
https://www.aetoswire.com/en/news/2610202228036
Contacts
Stacy Drumtra, Chicago
stacy.drumtra@egonzehnder.com | T: +1 312 260 8974

Martin Klusmann, Berlin
martin.klusmann@egonzehnder.com | T: +49 170 236 0101

Go Back

ICS® Diamond Tools and Equipment Is Rebranding to Oregon®

The industry leader in pipe and concrete precision cutting is harkening back to its heritage and assuming the name of the flagship brand that started it all 75 years ago

(BUSINESS WIRE)-- ICS® Diamond Tools and Equipment (ICS), the industry leader in pipe and concrete precision cutting, announced today that it will rebrand to Oregon®, which is a division of Oregon Tool, Inc. ICS® was founded as a project within Oregon® in the ’90s, and this transition will allow the company to continue to evolve while building on its legacy under the name of its flagship brand. Unifying the two brands is a natural next step in redefining what’s possible in the power cutter market.

The inspirational power of nature is what led Joe Cox to found Oregon Tool, Inc. and leave his mark as the creator of saw chains that revolutionized the industry. In the ’90s, a small team of people saw an opportunity to build on Oregon Tool Inc.’s strong foundation. The result was the creation of ICS®, which forged a path in designing and developing power cutters for individuals working with concrete and iron pipe. At the heart of it, ICS® has always been Oregon®, just a different brand.

“Intrepid, bold thinking is a deep-seated belief at ICS®, and we’re excited to continue providing that innovation, quality and performance as Oregon®,” said Paul Tonnesen, CEO of Oregon Tool, Inc. “We’re confident that the global recognition Oregon® has established will seamlessly integrate our brands and further showcase our tools as the top choices for professional and do-it-yourself users.”

We are taking bold steps that enable us to evolve and doing so as Oregon®. What’s important to remember is that while the ICS® name is changing, the commitment to our people, customers and product is not. We’re still the same great team supporting our customers when they’re in need of a superior tool for the job at hand – we’re just doing it with a great new look.

While we officially transition to the Oregon® brand on October 24, there will be a period where both ICS® and Oregon® products live in the marketplace together. To learn more, visit oregonconstruction.com.

About the Oregon Construction Business of Oregon® Products

Headquartered in Portland, Oregon, with distribution in 70 countries, Oregon® Products and its Oregon Construction Business invented the diamond chain cutting technology and has been the global leader in chain-based concrete and pipe cutting solutions for over 30 years. Because “good enough” isn’t good enough and equipment needs to show up and measure up, these products are tirelessly designed, engineered and manufactured to outwork the competition. Using best-in-class materials, our SealPro® anti-stretch technology reduces chain stretch to maximize chain life, and our patented PowerGrit® diamond cutting chain makes it safer and easier to cut ductile iron, HDPE and PVC pipe in confined spaces with significantly lower kickback risk. Oregon® diamond chain, guide bars and powerheads offer a cutting system with up to 25-inch cutting depth. Also, Oregon® powerheads are designed for wet cutting with integrated water-delivery systems that reduce airborne particles during the cut. Oregon® is part of the Oregon Tool, Inc. portfolio of brands. To learn more, visit oregonconstruction.com.


Permalink
https://www.aetoswire.com/en/news/26102022278034
Contacts
Hiebing: Lauren Smith
(608) 268-4408
lsmith@hiebing.com

 

Go Back

Schlumberger Announces Third-Quarter 2022 Results

-Revenue of $7.5 billion increased 10% sequentially and 28% year on year
-International revenue of $5.9 billion increased 13% sequentially and 26% year on year
-North America revenue of $1.5 billion was flat sequentially and increased 37% year on year
-GAAP EPS of $0.63 decreased 6% sequentially and increased 62% year on year
-EPS, excluding charges and credits, of $0.63 increased 26% sequentially and 75% year on year
-Cash flow from operations was $1.6 billion and free cash flow was $1.1 billion
-Board approved quarterly cash dividend of $0.175 per share

(BUSINESS WIRE) -- Schlumberger Limited (NYSE: SLB) today announced results for the third-quarter 2022.

Schlumberger CEO Olivier Le Peuch commented, “The second half of the year is off to a great start with strong third-quarter results that reflect the acceleration of international momentum and solid execution across our Divisions and areas. Sequentially, we delivered another quarter of double-digit revenue growth and margin expansion, as the pace of growth in our international business stepped up significantly, complementing already robust levels of activity in North America.

“On a companywide basis, sequential revenue grew 10%, by more than $700 million; EPS—excluding charges and credits—increased 26%; pretax segment operating margin expanded 161 basis points (bps) to reach 18.7%; and free cash flow was $1.1 billion. Both EPS—excluding charges and credits—and pretax segment operating margin represent their highest levels since 2015, as we continue to execute on our returns-focused strategy with much success.

“Year-over-year comparisons were exceptional with revenue growing by 28%; EPS—excluding charges and credits—increasing 75%; and pretax segment operating margin expanding 320 bps.”

Revenue growth was led by Well Construction and Production Systems as global activity strengthened—particularly in the offshore and international markets. Schlumberger’s leading position in these markets continues to propel strong and profitable growth in the Core. The quarter was also supported by continued backlog conversion, strong technology adoption, and the growing effects of pricing improvements. Reservoir Performance also grew, while Digital & Integration declined as growth in digital solutions was more than offset by the non-repeat of exploration data transfer fees recorded in the previous quarter.

International Torque Ramps Up as Revenue Exceeds Third-Quarter 2019 Level

Le Peuch said, “Third-quarter revenue was driven by International, which posted 13% growth sequentially and 26% year on year. International revenue also exceeded third-quarter 2019 levels, on a rig count that is still approximately 25% lower than in 2019. This comparison highlights the significant gains we have made in strengthening our market participation and our continued growth potential as rigs mobilize internationally in the quarters to come.”

Sequentially, growth was prevalent across all international areas led by Europe/CIS/Africa and Latin America, which increased 21% and 14%, respectively. This was driven by increased activity and higher pricing in Well Construction, in addition to higher Production Systems sales. Middle East & Asia revenue improved 8% sequentially due to increased multidivisional activity across Asia and higher Reservoir Performance revenue in the Middle East.

Outperforming in our Core—Strong Growth in Well Construction and Production Systems

Le Peuch said, “Our Schlumberger Core continues to perform extremely well as we continue to leverage our global breadth, leading technology portfolio, and pricing improvements to drive top- and bottom-line growth momentum.”

Revenue growth by Division was led by Well Construction with revenue increasing 15% sequentially, outperforming global rig count growth due to strong activity and pricing improvements in the Europe/CIS/Africa and Latin America areas. Similarly, Production Systems revenue grew 14% sequentially on higher product deliveries and backlog conversion, mostly in international offshore basins. Reservoir Performance revenue grew 9% due to higher intervention and stimulation activity, both on land and offshore, particularly in the Middle East & Asia and Europe/CIS/Africa areas. Year on year, revenue from all Divisions experienced double-digit growth, led by Well Construction, which grew 36%.

In relation to margin performance, Well Construction and Reservoir Performance led in sequential margin expansion having posted 403 bps and 209 bps growth, respectively. Year on year, Well Construction margin expanded 635 bps to reach 22%, due to broad pricing improvements and improved operating leverage.

Constructive Energy Fundamentals and a Supply-Led Decoupling of Upstream Investment

Le Peuch said, “While concerns remain over the broader economic climate, the energy industry fundamentals continue to be very constructive. Against the backdrop of the energy crisis and limited spare global capacity, the world faces an urgent need for increased investment to rebalance markets, create supply redundancies, and rebuild spare capacity. All of these are exacerbated by geopolitics and increasing instances of supply disruptions.

“These dynamics and the urgency to restore balance are resulting in a supply-led upcycle, characterized by the decoupling of upstream investment from near-term demand volatility. Furthermore, the need for sustained investments is reinforced by the long-term demand trajectory through the end of the decade and by OPEC+ decisions that are keeping commodity prices at supportive levels.

“Concurrently, we are witnessing a significant commitment from the industry to decarbonize oil and gas, with E&P operators all over the world deploying capital and adopting technologies—including digital—at scale, to reduce emissions. Taken together, we expect these constructive fundamentals and secular trends to support multiple years of growth.”

A Strong Finish in the Making for an Outstanding Year

Le Peuch said, “On a companywide basis, year-to-date revenue increased more than 20%; EPS on a GAAP basis grew 83%; EPS—excluding charges and credits—grew 67%; and pretax segment operating margin expanded 285 bps. I am very proud of these exceptional results delivered by the Schlumberger team as we approach the end of an outstanding year.

“As we close the year, we expect to deliver sequential revenue growth and margin expansion in the fourth quarter.

“To conclude, we have stronger conviction in our strategy and the opportunities across our three engines of growth—the Core, Digital, and New Energy. Constructive market fundamentals for oil and gas, energy security, and the urgency to accelerate the energy transition will support increased investment—in both clean energy technology development and lower carbon oil and gas production. We have positioned the company for long-term outperformance, with a diverse set of opportunities across the entire energy value chain. These technology-led opportunities cover oil and gas, industrial decarbonization, and new energy systems—all supported by digital transformation.

“Recent regulatory decisions and incentives reinforce our view of this compelling investment outlook and our strategic direction. We are prepared to apply our technology, global scale, and industrialization capabilities to lead in this energy landscape and deliver outstanding value for our customers and shareholders.

“I am truly excited about our future as we continue to drive innovation for a resilient and balanced energy system. I look forward to sharing at our upcoming Investor Conference, our views of the industry, revenue growth ambitions, earnings, and returns potential.”

Other Events

On August 30, 2022, Schlumberger, Aker Solutions, and Subsea 7 announced an agreement to form a joint venture to drive innovation and efficiency in subsea production to help customers unlock reserves and reduce cycle time. The agreement will bring together a portfolio of innovative technologies such as subsea gas compression, all-electric subsea production systems, and other electrification capabilities that help customers meet their decarbonization goals. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close in the second half of 2023.

In October 2022, Schlumberger redeemed $895 million of its outstanding notes, consisting of $600 million of 2.65% Senior Notes and $295 million of 3.625% Senior Notes, both due 2022.

On October 20, 2022, Schlumberger’s Board of Directors approved a quarterly cash dividend of $0.175 per share of outstanding common stock, payable on January 12, 2023, to stockholders of record on December 7, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019006128/en/


Permalink
https://aetoswire.com/en/news/2510202227999
Contacts
Investor Relations Contacts:
Ndubuisi Maduemezia – Vice President of Investor Relations, Schlumberger Limited
Joy V. Domingo – Director of Investor Relations, Schlumberger Limited
Office +1 (713) 375-3535
investor-relations@slb.com

Media Contacts:
Josh Byerly – Vice President of Communications, Schlumberger Limited
Moira Duff – Director of External Communications, Schlumberger Limited
Office +1 (713) 375-3407
media@slb.com

 

Go Back

Bacardi Cuts Plastic in Packaging

Removal of plastic pourers from bottles in the Bacardi portfolio will cut approximately 140 tons of plastic used annually

(BUSINESS WIRE)--Bacardi, the world’s largest privately held spirits company, is cutting approximately 140 tons of single-use plastic annually, by removing plastic pourers from its bottles in the U.S., Canada, Puerto Rico, Spain and Portugal.

The plastic Non-Refillable Fitment (NRF) is commonplace throughout the spirits industry and is currently found in the neck of a number of the company’s iconic drink brands including: BACARDÍ® rum, MARTINI® Fiero, BOMBAY SAPPHIRE® gin and DEWAR’S® White Label blended Scotch whisky.

The removal has already begun, and by early next year, all 1.75l bottles of BACARDÍ rum – including Superior, Gold and Coconut – in the U.S., Canada, and Puerto Rico will no longer contain the plastic pourer, cutting 76 tons of plastic annually.

In Spain and Portugal, the plastic pourer will be removed from all brands in the Bacardi portfolio over the next six months.

“We are making this bold move because it’s the right thing to do for the planet,” says Rodolfo Nervi, VP, Global Safety, Quality & Sustainability, Bacardi. “As a family-owned company for more than 160 years, pioneering change is in our DNA, and we’re proud to be leading the industry as we take another huge step towards achieving our commitment to be 100% plastic free by 2030.”

Bacardi is reviewing every way in which it is currently using plastic and exploring whether it can be removed or replaced with a more sustainable alternative. A major milestone will be reached in 2023, when the company will remove all single-use plastic from its gift packs and point-of-sale materials.

Rodolfo Nervi added: “Consumers will continue to enjoy the same exceptional quality and taste from our entire portfolio of brands as we continue on our journey to a more sustainable future.”

Find out more about Bacardi and its ESG – Environmental, Social & Governance – commitments, including its alignment with the United Nations Sustainable Development Goals, at www.bacardilimited.com/good-spirited.

Always drink responsibly.

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000 people, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005086/en/


Permalink
https://aetoswire.com/en/news/2510202228006
Contacts
Media enquiries:
Andrew Carney, Communications Director Western Europe, Australia & New Zealand, Bacardi, acarney@bacardi.com
Jessica Merz, VP Global Corporate Communications, Bacardi, jmerz@bacardi.com

 

Go Back

Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair

PHILADELPHIA - Tuesday, 25. October 2022 

Evan Tzanis was appointed to the role of Chief Operating Officer
Seth Schulman, M.D. joins as Chief Medical Officer
Conversion of all previous notes into preferred shares
 

(BUSINESS WIRE) -- Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.

Evan Tzanis has been appointed to the role of Chief Operating Officer and Executive Vice President of Research and Development. Mr. Tzanis had served in the role of Executive Vice President of Research and Development since joining Neuraptive in 2019, and will continue to report to Robert Radie, Chairman and CEO. Mr. Tzanis has led the company from a pre-clinical focused company to a clinical staged company with two active INDs cleared and two Phase 2 clinical studies ongoing with Fast Track designation. Additionally, Mr. Tzanis has played an integral role guiding the company through significant organizational transition and fundraising.

In addition, the company has hired Seth Schulman, M.D. as Chief Medical Officer reporting to Mr. Tzanis. Dr. Schulman had previously been consulting with the company. Dr. Schulman is a seasoned drug developer who held roles of increasing responsibility in clinical research from 2004 to 2019 at Wyeth and Pfizer pharmaceuticals, and in 2014, Dr. Schulman became Head of Clinical Sciences Excellence and Innovation in the Global Innovative Pharma Business Unit. Prior to joining Wyeth Pharmaceuticals, Dr. Schulman was a pediatric nephrologist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics and Surgery on the faculty of the University of Pennsylvania School of Medicine. Dr. Schulman has directly overseen hundreds of clinical trials and several product approvals across multiple therapeutic areas including neurology.

“The appointment of Mr. Tzanis to Chief Operating Officer recognizes his successful track record of building high-performing teams and delivering strong results,” said Robert Radie, Neuraptive’s Chairman and CEO. “His expanded role includes oversight and management of manufacturing, quality assurance, regulatory and other key internal company operations.”

“Dr. Schulman is a physician-scientist and clinical and operations leader with extensive experience overseeing and directing end-to-end clinical research and development studies, and I am pleased to have him as part of the Neuraptive team. The appointment of Mr. Tzanis and hiring of Dr. Schulman are aligned to the company's continued progress toward the eventual NDA filing for its lead program, NTX1-001.”

Finally, the company provided a financial update with the conversion of all previous debt into equity. Over $7.5M in notes converted into preferred shares as the company met certain triggering criteria. The company currently has no outstanding debt.

About Neuraptive

Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005766/en/


Permalink
https://www.aetoswire.com/en/news/2510202227991
Contacts
IR@neuraptive.com
or
+1-484-787-3203

 PHILADELPHIA - Tuesday, 25. October 2022 

Evan Tzanis was appointed to the role of Chief Operating Officer
Seth Schulman, M.D. joins as Chief Medical Officer
Conversion of all previous notes into preferred shares
 

(BUSINESS WIRE) -- Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.

Evan Tzanis has been appointed to the role of Chief Operating Officer and Executive Vice President of Research and Development. Mr. Tzanis had served in the role of Executive Vice President of Research and Development since joining Neuraptive in 2019, and will continue to report to Robert Radie, Chairman and CEO. Mr. Tzanis has led the company from a pre-clinical focused company to a clinical staged company with two active INDs cleared and two Phase 2 clinical studies ongoing with Fast Track designation. Additionally, Mr. Tzanis has played an integral role guiding the company through significant organizational transition and fundraising.

In addition, the company has hired Seth Schulman, M.D. as Chief Medical Officer reporting to Mr. Tzanis. Dr. Schulman had previously been consulting with the company. Dr. Schulman is a seasoned drug developer who held roles of increasing responsibility in clinical research from 2004 to 2019 at Wyeth and Pfizer pharmaceuticals, and in 2014, Dr. Schulman became Head of Clinical Sciences Excellence and Innovation in the Global Innovative Pharma Business Unit. Prior to joining Wyeth Pharmaceuticals, Dr. Schulman was a pediatric nephrologist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics and Surgery on the faculty of the University of Pennsylvania School of Medicine. Dr. Schulman has directly overseen hundreds of clinical trials and several product approvals across multiple therapeutic areas including neurology.

“The appointment of Mr. Tzanis to Chief Operating Officer recognizes his successful track record of building high-performing teams and delivering strong results,” said Robert Radie, Neuraptive’s Chairman and CEO. “His expanded role includes oversight and management of manufacturing, quality assurance, regulatory and other key internal company operations.”

“Dr. Schulman is a physician-scientist and clinical and operations leader with extensive experience overseeing and directing end-to-end clinical research and development studies, and I am pleased to have him as part of the Neuraptive team. The appointment of Mr. Tzanis and hiring of Dr. Schulman are aligned to the company's continued progress toward the eventual NDA filing for its lead program, NTX1-001.”

Finally, the company provided a financial update with the conversion of all previous debt into equity. Over $7.5M in notes converted into preferred shares as the company met certain triggering criteria. The company currently has no outstanding debt.

About Neuraptive

Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005766/en/


Permalink
https://www.aetoswire.com/en/news/2510202227991
Contacts
IR@neuraptive.com
or
+1-484-787-3203

 

Go Back

Andersen Global Strengthens Slovakian Presence with Leading Law Firm

(BUSINESS WIRE)--Andersen Global continues to extend its reach into Slovakia through a Collaboration Agreement with law firm CLS Čavojský & Partners, complementing the organization’s existing tax capabilities in the country.

CLS Čavojský & Partners, founded in 2006, is led by Managing Partner Peter Čavojský and operates out of Bratislava. The team of professionals provides full-service capabilities in corporate, labor, banking and insurance, competition, insolvency, real estate, compliance, public procurement and intellectual property rights. The firm is also consistently recognized by The Legal 500 and IFLR 1000.

“Over the years, our firm has been acknowledged as a leading law firm due to our client-focused approach and deep understanding of our clients’ needs,” Peter said. “Collaborating with the like-minded individuals of Andersen Global strengthens our firm’s growth trajectory as we continue to extend our global reach and capabilities to provide seamless service throughout the region and globally.”

“Peter and his team have consistently demonstrated their dedication to stewardship and best-in-class service, which will allow them to build strong working relationships with the member and collaborating firms in the region,” added Andersen Global Chairman and Andersen CEO Mark Vorsatz. “Our collaboration with CLS Čavojský & Partners enhances our global organization’s coverage as we continue to deliver integrated service globally.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 12,000 professionals worldwide and a presence in over 380 locations through its member firms and collaborating firms.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005063/en/


Permalink
https://www.aetoswire.com/en/news/25102022278004
Contacts
Megan Tsuei
Andersen Global
415-764-2700

Go Back

Urethral Stricture: BEES-HAUS Cell Therapy Approach Proven With Cell Engraftment by Urologists of Edogawa Hospital, Japan, Holds Potential to Prevent Recurrence.

Edogawa Hospital plans urethral reconstruction center, setting up Boron Neutron Capture Therapy (BNCT) for Cancer treatment.

(BUSINESS WIRE)--Urethral stricture, blocking the passage of urine from the bladder in men, could be solved by BEES-HAUS cell therapy, a novel autologous buccal mucosal cell-based approach as reported by Dr. Akio Horiguchi an eminent urologist. He has confirmed it for easy reproducibility in Japan, and cell engraftment at the site of urethral damage and scarring, the vital step to prevent stricture recurrence. Dr. Dmitriy Nikolavsky (Upstate University Hospital, New York), researching on urethral stricture lauded this feat. Dr. Suryaprakash Vaddi, who reported successful clinical outcome of BEES-HAUS in six patients, moderated their presentation in the XVII NCRM NICHE 2022, international regenerative medicine meet, co-sponsored by Edogawa Hospital.

Incidence of male urethral stricture that increases after 55, despite various treatment approaches such as minimally invasive endoscopic urethrotomy or dilatation and invasive surgical urethroplasty with buccal mucosal patch, is reported with recurrences. A novel polymer scaffold developed by Japanese scientists helped successful relief of urethral stricture through cell engraftment by BEES-HAUS cell therapy. With reconfirmation of cell engraftment both morphologically and immunohistochemically, Edogawa hospital is preparing for a larger study and their data presented in AUA 2022 has now been accepted for publication in Stem Cell Reviews and Reports. JBM Inc., the collaborators who were granted a patent in Japan for BEES-HAUS, have developed an efficient buccal tissue preservation solution, (OPTRACT Method), for transporting cells between the lab and hospital, to support the cell therapy procedure.

The Fujio Cup Quiz of NCRM NICHE 2022 was won by Hasna Firdaus Aryantha & Natasya Emmanuela, Bandung Institute of Technology, Indonesia; Vijaya Harini and Yoghalakshmi Nagarajan of Sri Ramachandra Institute of Higher Education and Research, Chennai, India emerged runners.

Edogawa Hospital, medical tourism & knowledge propagation hub: Congratulating Dr Horiguchi for the accomplishment, Dr Shojiro Katoh, President, Edogawa Hospital, said that their institute will continue inter-disciplinary translational research in addressing such unmet needs. They are establishing Boron Neuron Capture Therapy (BNCT) system, the latest and advanced, targeted cancer treatment and researching on efficient drug delivery systems for better uptake of boron, enabling an effective destruction of cancer cells. BNCT centre will be open for cancer patients from abroad after approvals, he added.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221023005121/en/


Permalink
https://www.aetoswire.com/en/news/24102022-101
Contacts
 
Samuel JK Abraham
info@gncorporation.com

 

Go Back

Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic

A new 24-month subgroup analysis looked at sustained clinical response in participants who received up to two doses of RBX2660 across age, sex, race, and number of prior CDI episodes

Two post hoc analyses of RBX2660 reviewed physical, mental, and social health-related quality of life (HRQL) data from PUNCH™ CD3 clinical program

An oral presentation of an ad hoc efficacy and safety analysis of Phase 3 data on first recurrence and comorbidities receives the American College of Gastroenterology’s Outstanding Research Award in Colon Category

(BUSINESS WIRE) -- Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Data was presented from a post hoc subgroup analysis (24-Month Sustained Clinical Response and Safety of RBX2660 in Participants with Recurrent Clostridioides difficile Infection: Subgroup Analysis; Poster number E0100) on the long-term efficacy and safety of RBX2660 in the PUNCH CD open-label Phase 2 trial. Participants in the trial were 18 years of age or older with either two or more episodes of rCDI treated with standard-of-care antibiotics after a primary CDI episode or two or more episodes of severe CDI requiring hospitalization. Treatment success was defined as the absence of CDI diarrhea for eight weeks after completing study treatment. Among the 142 participants treated with RBX2660 (evaluable population), sustained treatment response through six, 12, and 24 months after treatment, respectively, was achieved by 98%, 97.9%, and 93.5% of participants under 65 years of age and by 96.8%, 93.1%, and 88% of participants 65 years of age and older. Similar sustained response rates were observed in participants categorized by sex, race, and number of prior CDI episodes. The analysis also showed that treatment-emergent adverse events (TEAEs) were reported by a similar percentage of participants across demographic subgroups between 6-12 months (range: 31%-43%) and 12-24 months (range: 23%-37%). Most TEAEs were gastrointestinal and mild to moderate in severity.

“C. difficile infection represents a significant public health burden that can cause an unrelenting cycle of recurrence, impacting a person’s long-term health,” said Elizabeth Garner, M.D. M.P.H., Chief Scientific Officer, Ferring Pharmaceuticals, U.S.

Two additional analyses reviewed data from the PUNCH™ CD clinical program and included post hoc analyses suggesting an improvement in health-related quality of life (HRQL) for patients treated with RBX2660. HRQL impact was based on the Clostridioides difficile Health-Related Quality of Life Questionnaire (Cdiff32), a validated disease-specific instrument with three domains (physical, mental, and social), and a total score (all range from 0-100 with 100 being the best possible).

The first analysis (Health-Related Quality of Life in Patients with One Prior Episode of Recurrent Clostridioides difficile Infection: Results from the RBX2660 Phase 3 Randomized, Placebo-Controlled rCDI Trial [PUNCH CD3]; Poster number E0349), was a post hoc analysis of HRQL within an eight-week period for a subgroup of participants in the PUNCH CD3 trial who experienced a first recurrence. The analysis included 66 participants (76.7%) with Cdiff32 data at baseline and at week 8 (43 RBX2660, 23 placebo). Unadjusted analyses showed greater HRQL improvements with RBX2660 versus placebo for total score (13.5±5.7, p<0.05) and mental domain (16.2±6.0, p<0.01), with nonsignificant improvements for physical (11.9±6.1, p=0.07) and social (7.6±7.5, p=0.45) domains. Adjusted analyses showed statistically significant differences (all p<0.05) for total score (11.03, 95% confidence interval: [1.34; 20.72]), physical (10.74, 95% CI: [1.36; 20.13]), and mental (13.07, 95% CI: [2.02; 24.13]) domains.

The second post hoc analysis (Health-Related Quality of Life of Week 8 Responders and Non-Responders: Results from the RBX2660 Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides difficile Infection [PUNCH CD3]; Poster number E0348) included responder participants with no recurrence (n=178; 125 RBX2660, 53 placebo) and non-responder participants with C. difficile recurrence (n=7; 3 RBX2660, 4 placebo) in the PUNCH CD3 trial. Among responders, improvements from baseline to week 8 were statistically significant (all p<0.001) for both arms and all Cdiff32 scores. Adjusted analyses among responders found a difference favoring RBX2660 versus placebo at week 8 for the mental domain (7.4, 95% CI: [0.33, 14.43], P<0.05). Among non-responders, numerical improvements in all four scores were observed for RBX2660, while scores remained similar from baseline to week 8 for placebo.

“These two analyses suggest the potential for RBX2660 to help improve the health-related quality of life for patients with recurrent CDI,” said Paul Feuerstadt, M.D., F.A.C.G., A.G.A.F., Yale University School of Medicine.

Additional ACG 2022 Data Presentations

Four additional analyses were presented at ACG 2022, which looked at the efficacy and safety of RBX2660 across different populations, including participants with underlying comorbidities. These analyses included the following:

An ad hoc analysis of PUNCH CD3-OLS (An Interim Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of RBX2660 in Patients with Recurrent Clostridioides difficile Infection; Session number 56). PUNCH CD3-OLS is an ongoing, open-label phase 3 study evaluating the efficacy and safety of RBX2660. Enrolled participants were 18 years of age or older with medically documented rCDI, including first recurrence patients and broad eligibility criteria. After standard-of-care antibiotics, participants received a single dose of RBX2660. At the time of this analysis, 483 participants had received RBX2660. Treatment success was defined as remaining recurrence-free for 8 weeks after treatment and was achieved by 74.6% of participants whose outcomes could be analyzed (300/402), which is consistent with a 2021 ad hoc analysis. Among the RBX2660 responders (n=300) who completed six months of follow-up (n=262), 84% (220/262) remained CDI recurrence-free. TEAEs were reported by 69% of RBX2660-treated participants. Most TEAEs were mild to moderate in severity and gastrointestinal in nature, with diarrhea and abdominal pain the most commonly reported. This oral presentation received the American College of Gastroenterology’s Outstanding Research Award in Colon Category.
An ad hoc analysis from PUNCH CD3-OLS (Efficacy and Safety of RBX2660 in Reducing Recurrent Clostridioides difficile Infection in Patients with Underlying Gastrointestinal Comorbidities; Poster number D0099) involving a subgroup of participants from a modified intent-to-treat population (n=402) who had GI comorbidities (gastroesophageal reflux disease, irritable bowel syndrome, diverticulitis, irritable bowel disease, unspecified colitis). Among participants in this subgroup population, treatment success – defined as remaining free of CDI recurrence for eight weeks after treatment – was found among 75% of those treated with RBX2660. Additionally, six month adjudicated results found 84% of RBX2660-treated participants across GI comorbidity subgroups remained CDI recurrence free. A sustained clinical response through six months was maintained in RBX2660 participants with and without GI comorbidities. Overall, adverse events and TEAEs were similar between participants with and without GI comorbidities. Most TEAEs were mild to moderate in severity and GI in nature (predominantly diarrhea and abdominal pain).
A prespecified post hoc analysis of PUNCH CD3 (Efficacy and Safety of RBX2660 in Patients After First Recurrence of Clostridioides difficile Infection - Results from a Phase 3, Randomized, Placebo-Controlled Study; Poster number D0100), looked at the efficacy and safety of RBX2660 in a subgroup of participants with only one rCDI episode prior to study enrollment (86 of 276), who received a single blinded dose of RBX2660 or placebo. Treatment success, defined as remaining free of CDI recurrence for eight weeks after treatment, was achieved by 79.2% (42/53) of those treated with RBX2660 versus 60.6% (20/33) of those treated with placebo. Participants were monitored for recurrence through six months and the majority of responders remained recurrence free during this time period (RBX2660: 91% [38/42]; placebo: 85% [17/20]). TEAEs were reported by 54.7% (29/53) of RBX2660-treated participants and 33.3% (11/33) of placebo-treated participants, with mild events, mostly gastrointestinal, accounting for the difference.
A post hoc subgroup analysis of the PUNCH CD3 trial (Efficacy and Safety of RBX2660 in Patients with Recurrent Clostridioides difficile Infection Grouped by Age and Underlying Comorbidities; Poster number D0098), which assessed results from a modified intent-to-treat (mITT) population (n=262) grouped by age and underlying comorbidities using the Charlson Comorbidity Index (CCI) severity scores - mild, moderate, or severe. The CCI is a commonly used index that incorporates 16 conditions and age to estimate the risk of long-term mortality based on comorbidity burden, with severe CCI scores equating to a higher risk of death. Treatment success was defined as remaining CDI recurrence-free eight weeks after treatment. In the total mITT population, 71% of RBX2660-treated participants achieved treatment success compared with 62% of placebo-treated participants. The analysis found a greater percentage of RBX2660-treated participants remained recurrence-free compared to placebo-treated participants in most subgroups: <65: 75% vs. 76% (mild), 70% vs. 45% (moderate), 75% vs. 40% (severe); ages ≥65 to <75 years: 100% vs. 0% (mild), 74% vs. 63% (moderate), 73% vs. 50% (severe); ≥75 years: 50% vs. 100% (moderate), and 64% vs. 63% (severe). In the total safety population (n=267), the overall incidence of TEAEs was 52% for RBX2660-treated participants versus 42% for placebo-treated participants. Across subgroups, most TEAEs were mild or moderate in severity.
About C. difficile infection

C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe. The C. difficile bacterium causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea, and colitis (an inflammation of the colon).1 Declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC) requiring urgent and immediate action, CDI causes an estimated half a million illnesses and tens of thousands of deaths in the U.S. alone each year.1,2,3

C. difficile infection often is the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.4,5 It has been estimated that up to 35% of CDI cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections.6,7,8,9 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence.8,9

About RBX2660

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment. RBX2660 has been granted Orphan and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). RBX2660 was developed by Rebiotix, a Ferring company.

About the PUNCH™ CD3 Clinical Trial (Clinicaltrials.gov identifier: NCT03244644)

PUNCH CD3 is a Phase 3, prospective, multi-center, randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of RBX2660 vs. placebo in preventing rCDI. The study included adults ages 18 or older who had at least one recurrence after a primary episode of CDI. Participants were followed up to 8 weeks for the efficacy analysis, and up to six months for the safety analysis.

About the PUNCH™ OLS Clinical Trial (Clinicaltrials.gov identifier: NCT02589847)

PUNCH OLS is a Phase 2, prospective, multi-center, open-label study assessing the efficacy of RBX2660 compared to antibiotic-treated historical control. The study included adults ages 18 years or older who had at least two documented recurrent episodes of CDI after a primary episode and completed two rounds of standard oral antibiotic therapy or experienced at least two documented episodes of severe CDI resulting in hospitalization. The primary efficacy endpoint (treatment success) was defined as the absence of C. difficile associated diarrhea without the need for retreatment for CDI and was determined at the eight-week office visit. A secondary outcome was the safety profile of RBX2660 including adverse events and CDI occurrence through 24 months after treatment. A post hoc analysis evaluated RBX2660 responders who remained CDI occurrence free up to 24 months after treatment.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. Ferring is working to develop novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.

References:

Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available from: https://www.cdc.gov/cdiff/what-is.html

Centers for Disease Control and Prevention. Biggest Threats and Data, 14 Nov. 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html

Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile. Clin Microbiol Infect. 2012;18(suppl 6):2-4.

Centers for Disease Control and Prevention. 24 June 2020. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf

Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.

Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.

Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021;27(7):828-838. doi: 10.18553/jmcp.2021.20395. Epub 2021 Mar 11.

Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(suppl 6):21–27.

Smits WK, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi: 10.1038/nrdp.2016.20.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005022/en/


Permalink
https://www.aetoswire.com/en/news/2510202227995
Contacts
For more information

Lisa Ellen
Director, Brand Communications
+1-862-286-5696 (direct)
lisa.ellen@ferring.com

 

Go Back

Lenovo Unveils new Smarter Tech Innovations to Define the Future of the Digital World

HONG KONG - Wednesday, 19. October 2022 AETOSWire  

Innovations across form-factors, hybrid work technology, and Metaverse showcased at Lenovo’s flagship annual tech event Tech World ’22 – focused on making life better, work more productive, and the planet more sustainable

(BUSINESS WIRE) -- Lenovo today held its annual global innovation event, Tech World, sharing its vision for the evolution of collaboration across users, spaces, and devices to unlock unlimited possibilities in both real-world applications and the Metaverse. Lenovo unveiled new concepts, solutions, and emerging innovations that will define the way we work, learn, and engage in the digital world. The company also announced its vision for net-zero emissions, honing in on a credible and collaborative blueprint to addressing one of humanity’s greatest challenges.

Lenovo unveiled innovations including the first public showing of rollable proof of concepts for smartphones and laptop PCs. Infusing computing into rollable screens provides productivity, entertainment, and connectivity on a dynamic, adjustable, and larger screen, but on smaller device – addressing customer pain points and improving hybrid working productivity.

Also unveiled was the compelling interactive and physical holographic solution for immersive telepresence communication and teamwork, called Cyber Spaces. As data proliferation continues, Lenovo also showcased how its innovations, empowered by AI with edge computing, are enabling faster data processing at the source of its creation, transforming city streets, precision medicine, and shopping markets.

"Technology is transforming our future workspace and living space into a combination of virtual and physical worlds, enabled by the power of new IT infrastructure which is prevalent, expected and on demand,” said Lenovo Chairman and CEO, Yuanqing Yang. “The power of innovation is not only digitalizing and smartifying all industries but also helping solve humanity's greatest challenges. For that purpose, Lenovo is doubling our investment in R&D to use smarter technology to empower a rapidly changing world.”

At Tech World ‘22, Lenovo unveiled:

Rollable Form Factor Innovations

Lenovo and Motorola unveiled rollable proof of concepts for smartphones and laptop PCs, ushering in a new potential era where this unique form factor enables more content and offers huge possibilities for the future to improve hybrid work and life. Designed to elevate multi-tasking, browsing, and mobile use cases, the new rollable proof of concepts are compact, yet don’t sacrifice screen size – enabling content on screen to be dynamically adjusted to the device as the expandable screen rolls inward into the base of the laptop, and smartphone.

Innovations for Productivity

Lenovo Freestyle app enables universal control and collaboration between a tablet and PC, allowing users to seamlessly pair and transform their tablet into a portable second screen to extend desktop space or a wireless touchscreen for their laptop.

motorola edge smartphones include Ready For Platform, which extends smartphone capabilities to bigger screens and allows for a mobile desktop experience, console-like gaming, content streaming and video chats

Lenovo revealed its Remote Work Enablement solution, which delivers hardware, software, and premium services straight to employees, and allows remote workers to get set up quickly.

Lenovo also presented a future concept called Cyber Spaces, which replicate an immersive face-to-face experience by providing an interactive, physical holographic solution for telepresence communication and teamwork.

Additionally, the event saw new advancements in “virtual personas” or “digital humans,” to address challenges posed by traditional video conferencing, including bandwidth, quality, and privacy.

AI Solutions

Lenovo showcased its Production Decision Engine, which uses AI and big data to address digitalization pain points. Its Supplier 360 identifies, analyzes and mitigates supply chain risks to help plan for ‘what if’ scenarios.

The company also presented its Smart Services solution, which forecasts repair needs and optimizes the network of parts, service engineers and logistics support.

Lenovo demonstrated how its Virtual Classroom solution offers virtual teachers to students, providing personalized tests and recommendations.

The new remote video collaboration solution connects frontline workers with remote experts to perform repair jobs through real time marks.

Vision for Net-Zero by 2050

Lenovo shared its vision for net-zero emissions, and its first step toward that vision with near-term 2030 emissions reduction goals. Lenovo is aligning its emissions reduction goals to the Science Based Targets initiative in both the near and long-term to contribute to the goals of the Paris Agreement.

Lenovo highlighted the innovations that will help it realize its vision for net-zero, and the actions the company is taking across products and manufacturing to lower its carbon footprint.

Guest experts clarified the need for credible standards and collaboration between public and private entities in order to make progress toward a smarter, more sustainable future while clarifying the meaning and importance of net-zero commitments.

Edge and AI technologies Enabling Next-gen Data Processing

Lenovo and VMware announced an MOU for joint Edge and Cloud Innovation Labs, with plans underway to develop co-engineered edge, AI and multi-cloud solutions that will help accelerate business transformation across manufacturing and retail environments.

Lenovo showcased its ThinkEdge series of servers – including SE350 and SE450 – to show how the servers perform well under extreme conditions, with top-performance GPUs to support heavy AI .

Lenovo also presented XClarity, a unified, open cloud software management platform that simplifies IT orchestration, deployment, automation, metering, and support from edge to cloud. The company also showcased its Edge Cloud Platform, which enables various applications across vertical industries as well as its Hybrid Cloud Solution, which covers the full lifecycle of building, migrating, using and managing hybrid cloud.

Additionally, TruScale, an all-inclusive, subscription-based model, has expanded to more customers.

Lenovo also unveiled the findings of its global multi-industry research study of 500 chief technology officers (CTOs). The study uncovered CTO’s viewpoints on how traditional IT will continue to evolve into a ‘New IT’ architecture where client devices, edge computing, cloud computing, network and AI all work together to address common pain points and provide solutions that drive further global digitalization across all industries.

Tech World ‘22 coincides with Lenovo’s global Think30 celebration, honoring 30 years of ThinkPad’s and ThinkSystem’s purposeful design and engineering innovation. Building on this legacy, the company unveiled the broadest enterprise portfolio enhancement in its history, designed to accelerate global IT modernization with the new Lenovo Infrastructure Solutions V3, and celebrated over 200 million ThinkPad devices sold. Lenovo continues to redefine device innovations, including with the recent launch of the new ThinkPad X1 Fold, the next generation of the world’s first foldable PC.

Lenovo Chairman and CEO, Yuanqing Yang delivered the Tech World ‘22 keynote speech and shared insight into how Lenovo’s smarter technology is empowering people everywhere to change their world for the better.

In the keynote, Yang was joined by Lenovo business leaders and leading global CEOs, including Cristiano Amon, President and CEO of Qualcomm; Pat Gelsinger, CEO of Intel; Julie Sweet, Chair and CEO of Accenture; as well as Lisa Su, CEO of AMD, and Arvind Krishna, Chairman and CEO of IBM. Customers and partners including Stefano Domenicali, President and CEO from Formula 1® and Panos Panay, Executive Vice President and Chief Product Officer from Microsoft also discussed the role of Lenovo’s smarter technology in empowering intelligent transformation.

Dr Yong Rui, Lenovo’s Chief Technology Officer, discussed how Lenovo will develop Metaverse tech solutions to empower intelligent transformation. He highlighted how Lenovo’s core technology and innovations across devices, servers, software, and solutions will connect the virtual and physical worlds.

During the main keynote session, Luca Rossi, President of Lenovo’s Intelligent Devices Group, presented new future concepts. From consumer innovations that improve life to productivity and collaboration solutions, new form factors like the rollable laptop PC and smartphone proof of concepts, and even emerging AI and Metaverse solutions like the new Lenovo ThinkReality VRX virtual reality solution will empower future generations as they navigate the digital transformation of our evolving world.

Kirk Skaugen, President of Lenovo’s Infrastructure Solutions Group, presented the evolution of computing everywhere. Kirk discussed the need to immediately harness data across all industries to intelligently transform. Lenovo’s smarter infrastructure is enabling this transformation, via servers, storage, and services. Kirk was joined by leaders from VMware and the Barcelona Supercomputing Center as he showcased how Lenovo is leading AI at the edge to help customers harness the power of the global data growth (expected to double by 2025) happening across today’s changing IT landscape.

Ken Wong, Executive Vice President and President of Lenovo’s Solutions & Services Group, discussed how the role of a CIO has expanded as the world digitizes. Ken also highlighted the value of industrial Metaverse solutions, the importance of digital workspace solutions and how optimizing track management for engineers can improve infrastructure such as public transportation, in real time. Claudia Contreras, Executive Director of Lenovo’s Global Sustainability Services also highlights that Lenovo’s services can help customers work toward their own sustainability goals, no matter where they are in their journey.

Laura Quatela, Senior Vice President and Chief Legal Officer at Lenovo highlighted the ways Lenovo is working toward enhanced sustainability across its product offerings on its journey to net-zero. In addition to sustainable product innovations, Laura shares sustainable improvements Lenovo is making to lead the way in low-emissions manufacturing, as well as Lenovo’s intentions to share and report its progress for a credible, collaborative approach to emissions reduction. These sustainability efforts were bolstered by Yang’s closing announcement of Lenovo’s commitment to a vision for net-zero by 2050.

Visit Lenovo’s Tech World ’22 homepage for full specs, images, and more information.

About Lenovo:

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into key growth areas including server, storage, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com,and read about the latest news via our StoryHub.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005976/en/


Permalink
https://www.aetoswire.com/en/news/1910202227873
Contacts
Stuart Gill
sgill@lenovo.com

Go Back

Sidra Capital Announces the First Close of an Asia-Pacific Private Equity Co-Investment Strategy With BlackRock Alternatives

(BUSINESS WIRE)--Sidra Capital, the Saudi based alternative asset manager, partners with BlackRock Alternatives to announce the first close of the Sidra-BlackRock Asia-Pacific Private Equity Strategy. The bespoke strategy looks to provide investors with unique Shari’ah compliant private equity opportunities in the Asia-Pacific (APAC) region.

The strategy leverages BlackRock’s established GP network and strong deal flow to access leading managers with compelling transactions. The strategy is structured to provide investors with a diversified exposure to the APAC region. APAC comprises of countries located in the East, South, and Southeast Asia as well as Australia and Oceania.

"This new mandate takes a strategic approach to a region that is rich with investment opportunities,” said Hani Baothman, Chairman of Sidra Capital. "Partnering BlackRock's strong fiduciary heritage and expertise in the region with Sidra's successful track record in Shari’ah compliant investments worldwide, will offer investors a truly unique investment opportunity in the APAC region."

Lynn Baranski, Global Head of Investments for BlackRock Private Equity Partners said: "Private markets in Asia are gradually becoming an integral part of private portfolios for clients across the globe on the back of robust economic and investment development. We see ample investment opportunities to deliver attractive risk-adjusted returns in the region for experienced managers with on-the-ground presence and proven track records across cycles."

Private equity earned a combined IRR of 27% in 2021 and remained the highest-performing private markets asset class, with manager selection and sub-asset class allocation reported as having a significant bearing on overall portfolio performance. APAC private equity has consistently outperformed its public market peers in the past 5-, 10-, and 20-year periods. APAC PE deal activity was up 50% to USD 296 billion in 2021 with China and India contributing the most to the deal volume (43% and 21%, respectively), followed by South Korea.

The APAC region is particularly attractive as its expanding middle class is experiencing an increased demand for consumer goods, utilities, TMT, healthcare and education. Investment opportunities range from developed Asia to emerging economies where there is a new wave of activity. In addition, there is strong potential in under-penetrated private markets.

About Sidra Capital

Sidra Capital is a leading alternative asset manager and internationally recognized as a leader in the growing Shari’ah compliant investment industry. The company has a successful track record working with best-in-class regional and global sponsors and asset managers to structure Shari’ah compliant private equity investment opportunities for its investors. Sidra’s private equity strategic focus is global and covers the entire spectrum of private equity disciplines, including buyouts, growth capital, recapitalizations and venture capital.

About BlackRock Alternatives

BlackRock Alternatives serve investors seeking outperformance in real estate, infrastructure, private equity, credit, hedge funds and alternative solutions. We strive to bring our investors the highest quality investments by drawing upon our global footprint, superior execution capabilities and position as a preferred partner. BlackRock manages $313 billion in alternative investments and commitments on behalf of clients worldwide as of September 30, 2022.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221023005099/en/


Permalink
https://www.aetoswire.com/en/news/2410202227962
Contacts
Media
Sidra Capital
prandmarketing@sidracap.com

Go Back

Stern Pinball Launches New The Mandalorian™ Topper Pinball Machine Accessory

CHICAGO 
(BUSINESS WIRE) -- Stern Pinball, Inc., announces a new state-of-the-art The Mandalorian pinball Topper accessory compatible with the Pro, Premium, and Limited Edition (LE) models of The Mandalorian.

The Mandalorian is a critically acclaimed, Emmy-winning hit original series, streaming exclusively through Disney+. The series follows the travails of a lone gunfighter in the outer reaches of the galaxy, teaming up with key allies and protecting Grogu, while battling dangerous enemies and forces across their journey.

The Mandalorian-inspired Topper accessory introduces exclusive new gameplay features while transporting the player inside the cockpit of the Razor Crest™, using a 3D holographic display in vivid color. New gameplay features include Mandalorian Madness™, a mini wizard mode, and Beskar™ Bonanza, a progressive mode that awards all upgrades in the Foundry™.

The Mandalorian-inspired Topper leverages the Stern Insider Connected™ platform to enhance the gameplay experience. In addition to a player’s username and icon, the topper displays a player’s lifetime Encounter upper mini playfield accuracy percentage, plus lifetime Beskar™ collected for all games played while logged in to their Insider Connected player account. Players can also earn exclusive Insider Connected Achievements. The Topper comes equipped with Competition Mode functionality, displaying all player scores with the current high score being highlighted.

“The Mandalorian-inspired Topper is a game changer for The Mandalorian pinball playing experience,” said Gary Stern, Chairman and CEO of Stern Pinball, Inc. “This innovative and interactive topper will keep players connected with stunning visuals and all new features never achieved through a pinball topper accessory before.”

Pricing and Availability:

Manufacturer’s Suggested Retail Price: $US 1,999

MSRP for sales to USA end-users, before any VAT, GST, Sales Tax, Duties, or other taxes.

The Mandalorian-inspired pinball machines and accessories are available now through authorized Stern Pinball distributors and dealers around the world.

About Stern Pinball, Inc.

Stern Pinball, Inc. is a global lifestyle brand based on the iconic and outrageously fun modern American game of pinball. Headquartered minutes from Chicago’s O’Hare International Airport in the heart of North America, the company creates, designs, engineers, manufactures, markets, and distributes a full line of technologically advanced terrestrial and digital pinball games, parts, accessories, and merchandise. Stern Pinball serves digital, consumer, commercial, and corporate markets around the globe.

Recent Stern Pinball titles include James Bond, Rush, Godzilla, The Mandalorian, Led Zeppelin, Teenage Mutant Ninja Turtles, Stranger Things, Elvira’s House of Horrors, Jurassic Park, Black Knight: Sword of Rage, The Munsters, The Beatles, Iron Maiden, Aerosmith, Ghostbusters, KISS, Metallica, Game of Thrones, The Walking Dead, Star Trek, AC/DC, and Batman. A broad range of players enjoy Stern Pinball’s games from professional pinball players who compete in high-stakes competitions around the globe to novice players who are discovering the allure of the silver ball for the first time. To join the fun and learn more, please visit www.sternpinball.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005032/en/


Permalink
https://www.aetoswire.com/en/news/2010202227911
Contacts
Zach Sharpe
zach.sharpe@sternpinball.com

Go Back

THIS HALLOWEEN, ENTER THE REALM OF DREAM AT SKY2.0

Dubai, United Arab Emirates
This opulent d3 club promises a mischievous weekend like no other!

SKY2.0 is hosting a Halloween Special weekend on 27, 28, and 29 October. The sphere-shaped venue will undergo a significant makeover to ensure a lavish Halloween atmosphere. Get ready to enter a realm of imagination where eccentric outfits and ecstatic performances are routine. The glamourous club is expected to go through a complete re-arrangement inspired by dreams and fantasies for the occasion. An incredible snag tree rises in the heart of the venue, surrounded by sumptuous hanging chandeliers and enchanted clouds that change colors to reflect your darkest imagination. A costume competition will take place each night of the weekend. Dress up in your most spectacular costume for a chance to win a surprise!

Festivities start with B.I.G (Black Is Gold) on Thursday 27, the OG night that takes you on a journey through the sickest HipHop and AfroBeats hits. BOOMBOX brings back your favorite iconic hits on Friday 28 for a night of good energy and unbelievable tunes. SIGNATURE SATURDAY, the grand finale set to take place on Saturday 29, immerses partygoers in a musical adventure of House and HipHop. Don’t fancy going home early? No problem! You can dance your night away under the stars until 4 am. Walk-ins are welcome.

Along with creative and classy beverages, SKY2.0 offers the tastiest bites to fulfill your midnight cravings. The Asian menu brings in a wide assortment of starters, sushi rolls, and platters. From edamame to 50-piece sushi platters, SKY2.0 has something for every appetite.

What: SKY2.0 Halloween Weekend

When: 27, 28, & 29 October

Opening Times: Thursday, Friday, and Saturday | 10:30 pm to 4.00 am

Where: Dubai Design District Booking: Call +971 4 587 6333

 Website: www.skydubai.com

 Instagram: @sky2.0dubai

For images, please click here

Following the success of SKYBAR Beirut, SKY2.0 brings a new and interactive experience into the heart of the Dubai Design District. An unforgettable night is guaranteed at this clubbing powerhouse, with bountiful outdoor space, a phenomenally lavish setting, and unparalleled entertainment. With first-class global scale service, top-notch food and beverages, and grand lighting design, SKY2.0 comes to life every week with its iconic nights.


Permalink
https://www.aetoswire.com/en/news/2010202227888
Contacts
For media requests, please contact:

Amir Borro | amir@skydubai.com | +971529577791

Go Back

LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents

BALLERUP, Denmark - Friday, 21. October 2022 

Adtralza, a biologic that targets and neutralizes the interleukin (IL)-13 cytokine1, is now approved in Europe for adolescents with moderate-to-severe atopic dermatitis.2
(BUSINESS WIRE) -- NOT FOR DISTRIBUTION IN THE UK OR IRELAND

LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has extended the marketing authorization for Adtralza® (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

“Safety is a priority when selecting a treatment option for adolescents living with moderate-to-severe atopic dermatitis, as it can be a chronic and life-long condition,” said Dr. Andreas Wollenberg, dermatologist, allergist, and Professor in the Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Germany, and ECZTRA 6 clinical trial investigator. “In the ECZTRA 6 trial, we found the safety and efficacy data of Adtralza to be consistent with adult trials and ongoing long-term safety studies. These findings support the use of this new biologic that specifically targets IL-13 in adolescent patients.”

The approval is based on data from the Phase 3 ECZTRA 6 trial, which evaluated the efficacy and safety of Adtralza (150 mg or 300 mg) monotherapy compared to placebo in adolescents with moderate-to-severe AD who were candidates for systemic therapy.3 The approved dose for adolescent patients is an initial dose of 600 mg followed by 300 mg administered every other week, which is the same dosing as for adult patients.2

“Moderate-to-severe atopic dermatitis significantly impacts the lives of adolescents living with the condition, who cope with the discomfort of itch, the challenges of sleep loss and mental health impacts while also navigating this formative period when they transition to adulthood,” said Korey Capozza, MPH, Founder and Executive Director, Global Parents for Eczema Research (GPER). “This group currently faces limited treatment options, and the addition of more options is a positive development for young people living with moderate-to-severe AD.”

The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein.

“The European Commission’s approval of Adtralza for use in adolescent patients is a demonstration of our relentless commitment to bringing new treatment options to those living with atopic dermatitis,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma A/S. “Today’s announcement enables us to address the unmet needs of a broader patient population as we look forward to working with key stakeholders across Europe to make Adtralza available to adolescent patients who need it.”

About the ECZTRA 6 Trial

ECZTRA 6 (ECZema TRAlokinumab trial No. 6) is a randomized, double-blind, placebo-controlled, parallel-group, multinational 52-week trial, with 289 patients aged 12 to 17 (195 Adtralza patients and 94 placebo patients) in the full analysis set, evaluating the efficacy and safety of Adtralza (150 mg or 300 mg) monotherapy compared to placebo in adolescents with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.3,4

Following a washout period, patients were randomized to subcutaneous Adtralza 150 mg or 300 mg Q2W, or placebo for an initial 16 weeks. Adtralza dosing started with a 300 mg or 600 mg loading dose on day 0 for those receiving Adtralza 150 mg or 300 mg Q2W, respectively.3

At Week 16, patients who responded to Adtralza with an IGA score of 0/1 and/or EASI change of at least 75% from baseline, without use of rescue treatment, were re-randomized to Adtralza Q2W or Q4W for an additional 36 weeks. Patients not achieving primary endpoints at Week 16, those receiving rescue treatment from Week 2 to Week 16, and those meeting other specific criteria were transferred to open-label treatment of Adtralza 300 mg Q2W plus optional mild-to-moderate strength topical corticosteroids.3

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.5 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.6 Type 2 cytokines, including IL-13, play an important role in the key aspects of atopic dermatitis pathophysiology.1

About Adtralza® (tralokinumab)

Adtralza® (tralokinumab) is a high-affinity human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine7, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.1,2 Adtralza specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).1,7

Adtralza is approved for the treatment of adults and adolescents with moderate-to-severe AD in the European Union and approved for adults with moderate-to-severe AD in the United States, Great Britain, Canada, the United Arab Emirates, and Switzerland.2 Adtralza is marketed in the United States under the tradename AdbryTM (tralokinumab-ldrm). Applications to extend the indication of Adtralza/Adbry to adolescents are currently under review with several agencies, including the U.S. Food and Drug Administration (FDA).

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

References

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54-62
Adtralza® (tralokinumab) EU Product Information. LEO Pharma; October 2022.
Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. Fall Clinical. Oct. 21-24, 2021. Poster Presentation.
ClinicalTrialsRegister.eu. Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Identifier: 2017-005143-33.
Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387:1109-1122.
Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46.
Popovic B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429:208–19.
 

MAT-60133 October 2022

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019006173/en/


Permalink
https://www.aetoswire.com/en/news/2110202227936
Contacts
David Patti
LEO Pharma, Global Product Communications
+1.973.796.7706
DAPAI@leo-pharma.com

Go Back

Fast and Speedy! Vape Giant VOOPOO Released the Fast charging and Futuristic ARGUS P1

(BUSINESS WIRE) -- On 18th October, the vape giant VOOPOO, which is famous for its popular DRAG product, officially released its latest Pod, ARGUS P1 on its website. ARGUS P1 is featured with the 15W PD fast charging and futuristic mechanical design, which will refresh your impression toward POD E-cigarette!

15W PD Lightening Charging Effectively Shortens Charging Time

ARGUS P1, with a built-in 800mAh battery and supporting USB-PD charging adapter, is equipped with 15W PD fast charging, which charges the battery from 0 to 80% within 12 minutes. It only takes one cup of coffee time to charge from 0 to 100%. It is the vape that keeps you away from the anxiety for battery life.

Futuristic Mechanical Design Reflects the Collection-level Craftsmanship

ARGUS P1 demonstrates a futuristic and mechanical style in a half-metal, half-transparent design. Each finish of the five different colors brings users a unique experience. Made with tough zinc alloy, with the high fluidity of the smooth angles design, which are smooth and delicate to the touch and comfortable and natural in the grip. Besides, the visible circuit board, in which the GENE.AI 1.2 chip is shown in the product design for the first time, is the “real intelligence” and charm of science and technology impressing users with a stunning appearance. The four LED indicators with innovative optical design make the light soft and transparent and indicate the real-time power, exquisite and practical. The simple design gives a glimpse of VOOPOO's extraordinary technological strength.

GENE.AI 1.2 Senses Puffing Pressure and Adjusts the Output

GENE.AI 1.2 features automatic power adjustment, which provides optimal power setting by sensing each puff without manually adjusting or mode switching, easy-to-operate and energy-saving. Besides, GENE.AI 1.2 provides 6 protections including 8s overtime protection, short-circuit protection, overcharge protection, low battery protection, output over-current protection and chip over temperature protection.

ITO Atomization Technology Brings Delightful Taste and Flavor

ARGUS P1 is equipped with the innovative ITO platform for MTL. The unique drainage tank design speeds up oil delivering, and the special heating coil makes a larger heating area. They realize smoother transmission of nicotine salt and sufficient atomization, bringing users the ultimate rich taste experience.

Choose ARGUS P1 and enjoy the infinite charm of super-fast charging. Let the joy of vaping never cease!

About VOOPOO

VOOPOO was established in 2017 and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. As a high-tech enterprise with R&D, design, manufacturing, and branding, VOOPOO has four major product series — ARGUS, DRAG, VINCI, and V. Currently, VOOPOO has a presence in more than 70 countries in North America, Europe, and Asia.

Website: https://www.voopoo.com/

Instagram: https://www.instagram.com/voopootech_official/

Facebook: https://www.facebook.com/voopooglobal

YouTube: https://www.youtube.com/c/VOOPOO

Tiktok: https://www.tiktok.com/@voopoofans

Shop: https://shop.voopoo.com/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005607/en/


Permalink
https://www.aetoswire.com/en/news/2110202227932
Contacts
Nical Zhang
PR Manager
Nical.zhang@voopootech.com

Go Back

New iPhone Mount with MagSafe from Belkin designed for Apple’s Continuity Camera

LOS ANGELES
Introducing two elegantly designed options for Mac laptops, desktops and external displays

(BUSINESS WIRE)--Belkin, a global consumer electronics leader, today announces the iPhone Mount with MagSafe for Mac laptops, and the iPhone Mount with MagSafe for Mac desktops and displays. These mounts use MagSafe to connect to the iPhone and are elegantly secured to the Mac, and work great with Continuity Camera — a new feature in macOS Ventura that enables Mac customers to use their iPhone as a webcam. The iPhone Mount with MagSafe is perfect for hands-free streaming or chatting, and complements video conferencing apps like FaceTime, and innovative Continuity Camera features like Desk View that come with macOS Ventura.

“Belkin designs beautiful peripherals and innovative accessories for Apple’s incredible lineup of products, and the new iPhone Mount with MagSafe is the latest example,” said Steve Malony, CEO, Belkin International. “Continuity Camera is an incredible feature in macOS Ventura, and we are confident that our premium quality, materials engineering, and industrial design will make the experience for Mac and iPhone users even better.”

Available in two options for Mac laptops and Mac desktops and displays, the iPhone Mount with MagSafe allows users to magnetically attach iPhone to a Mac and use its powerful camera system as a webcam. Both mounts allow iPhone to stay securely in portrait or landscape orientations. Premium finishes and bold design complement the elegant Mac and iPhone aesthetic. In addition, the versatile iPhone Mount with MagSafe for Mac laptops is built with a ring grip for on-the-go usage, or as a convenient kickstand. The robust iPhone Mount with MagSafe for Mac desktops and displays supports adjustable viewing angles from vertical to 25 degrees downward tilt.

Product features:

Holds iPhone securely in place for hands-free streaming or chatting in portrait or landscape orientations
Attaches and detaches to Mac with no special tools required
Keeps Mac safe from scratches and doesn’t interfere with everyday functions
Premium finishes and durable design complement Mac and iPhone setup
Pricing and Availability:

The iPhone Mount with MagSafe for Mac laptops is now available to order for $29.95 USD on apple.com and select Apple Store locations worldwide.
The iPhone Mount with MagSafe for Mac desktops and displays will be coming soon.
Imagery

Hi-res imagery for all products can be found here:
https://www.dropbox.com/sh/cq499je1avuhtld/AAAzUdQ6oAMGueK2C-kq3pcba?dl=0

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018006013/en/


Permalink
https://www.aetoswire.com/en/news/1910202227861
Contacts
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com

Go Back

Best's Market Segment Report: Opportunities Arise for MENA Reinsurers Amid Divergent Economic Conditions

LONDON
(BUSINESS WIRE) -- Hardening reinsurance market conditions in the Middle East and North Africa region, as well as changes in reinsurers’ appetites as to where they deploy their capital, have sustained the positive price momentum over recent renewal seasons, according to an AM Best report.

The Best’s Market Segment Report, “Opportunities Arise for MENA Reinsurers Amid Divergent Economic Conditions,” notes that reinsurance capacity in the region continues to be highly changeable and dynamic against a backdrop of divergent economic conditions across the region for oil-exporting and oil-importing countries.

AM Best analysts also state that operational challenges and deteriorating country risk landscapes in several countries in the region have weighed negatively on their view of the financial strength of the reinsurers domiciled and operating in these countries. While several companies have experienced Long-Term Issuer Credit Rating downgrades over the past year, on the whole, MENA reinsurers rated by AM Best tend to demonstrate risk-adjusted capitalisation assessed at the strongest level, which is reflective of significant capital buffers relative to their operational exposures.

To access a complimentary copy of this market segment report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=325008.

For additional global reinsurance-related reports, including AM Best’s annual ranking of the Top 50 global reinsurance groups and in-depth looks at the insurance-linked securities, Lloyd’s, life reinsurance and regional reinsurance markets, please visit Best’s Research.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2022 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221016005016/en/


Permalink
https://www.aetoswire.com/en/news/1710202227790
Contacts
Emily Thompson
Financial Analyst
+44 20 7397 0291
emily.thompson@ambest.com

Richard Banks
Director, Industry Research – EMEA
+44 20 7397 0322
richard.banks@ambest.com

Alex Rafferty
Associate Director, Analytics
+44 20 7397 0312
alex.rafferty@ambest.com

Edem Kuenyehia
Director, Market Development & Communications
+44 20 7397 0280
edem.kuenyehia@ambest.com

Go Back

70% Of CEOs Say Their Network Is Slowing Business Growth, New NTT Study Finds

NTT’s new 2022 Global Network Report surveyed more than 1,300 enterprise networking professionals globally, uncovering a need for network modernization to enable business growth 

70% of CEOs globally say their level of network maturity is negatively affecting business delivery
72% of top performing businesses already outsource more than half of their network infrastructure
The top trends driving modernization of the enterprise network are: cybersecurity, cloud-native platforms, and the hybrid workplace
94% of business leaders are increasingly looking to partner with a Managed Service Provider or single specialist provider
(BUSINESS WIRE) -- NTT Ltd., a leading global IT infrastructure and services company, has today launched its 2022 Global Network Report, which found that 70% of CEOs believe their network maturity level is negatively affecting their business delivery. The adoption of hybrid, distributed work environments with multiple connected devices is erupting through enterprises but, despite investments, just two in five businesses say they are very satisfied with their current network capabilities. This has resulted in a new era of network modernization, with the majority of executives relying on it to enable business growth (>90%), and support artificial intelligence (AIOps) (91%).

Keeping hybrid environments secure
With distributed hybrid work models presenting far more attack opportunities for malicious actors, the importance of network security has become a major component of network architecture. This has inspired organizations to move to more centralized, cloud-based security solutions and a managed endpoint security model, as well as increasing their investments in network cybersecurity. Most business leaders believe new threats will drive increased security demands for their enterprise network, requiring a deeper level of access control and inspection (93%).

The transformation to network as a service models
Respondents reported that their highest concerns, above even cost, are security, modernization, and access to a full suite of services from their provider. In terms of managing the network, more than 90% of senior executives prefer the network as a service model, citing the flexibility to scale up and down as a major benefit. Additionally, a complexity in deploying effective AIOps and automation solutions, which simplify ongoing network operations but are complex to configure initially, make the network as a service model more attractive.

“Levels of investment in the network have surged, with the results of this research showing many organizations are leaning towards key partners and managed service solutions to fulfil their requirements. This is primarily to drive security and gain access to skills that can both optimize capability and accelerate innovation-based advances,” said Amit Dhingra, Executive Vice President at NTT Ltd. Network Services.

Dhingra concludes, “We are in the midst of a modernization of network services, however, many of the solutions that are currently in play for a minority will become standard within just two years. Instead, organizations should turn their attention to a network as a service model. Businesses should consider security, skills competency, ability to scale, private 5G, and software defined networking when selecting a network service provider. In the long term, blockchain, further AI and automation, AR and VR, quantum networking, 6G and photonic computing will affect how networks are delivered.”

Chris Barnard, Vice President at International Data Corporation (IDC) comments, “As new ways of working drive transformation, high performing enterprises realize the value of investing in strategic technologies – core enterprise networks, 5G, edge and artificial intelligence. To support the networking requirements of emerging digital services and applications, organizations are modernizing their enterprise networks, allowing for more efficient use and management of the networks that underpin their enterprises. Enterprises that have not invested risk negatively affecting their growth opportunities. As the network plays a fundamental role in digital transformation strategies and distributed working and processing, we can expect to see more enterprise network upgrades as technologies such as AI and security defenses are layered on to mainstream enterprise networking. While it can seem complex, service providers such as NTT can evaluate flexible deployment options that drive business value.”

The report concludes with seven considerations for executives to evolve and future-proof their network. Read the full 2022 Global Network Report here.

NTT Ltd. is a leader in the Gartner® Magic Quadrant™ for Enterprise Network Services, Global, positioned highest for both its “Completeness of Vision” and “Ability to Execute” among 18 network service providers.

-ENDS-

Methodology

The report is based on research conducted by Jigsaw Research on behalf of NTT Ltd. across 21 countries in five regions in July and August 2022. The research spanned 16 industry sectors including: retail and wholesale, manufacturing and automotive, financial services, technology and health. The research is based on a sample of network decision-makers/influencers in IT and wider business roles.

About NTT Ltd.

As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future.

Visit us at services.global.ntt

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005120/en/


Permalink
https://www.aetoswire.com/en/news/2110202227929
Contacts
Media Enquiries:
Hotwire for NTT Ltd.
Hannah Lock
ntt@hotwireglobal.com

Go Back

The Coretec Group Announces Matthew Hoffman as Chief Operating Officer

ANN ARBOR, Mich. - Wednesday, 19. October 2022

Hoffman will transition into the new role as the Company sets a stronger focus on operations

(BUSINESS WIRE) -- The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium-ion batteries and cyclohexasilane (CHS) for EV, cleantech, and emerging tech applications, today announced that Matthew Hoffman, the Company’s current Chief Financial Officer (CFO), will be taking on the additional role of Chief Operating Officer (COO), as the Company’s operational activities increase and become more complex.

As The Coretec Group’s operations are increasing, a COO-level leadership is needed, and Mr. Hoffman was the logical choice.

Hoffman’s background includes leadership roles of multiple early-stage high growth companies, covering the industries of energy, manufacturing, defense contracting and bio-technologies. Hoffman brings a valuable knowledge base to The Coretec Group operations from his past experiences with M&A, strategic and operational planning, business system architecture, ISO 9000, and a LEAN focus on business process improvement.

His previous experience with government funding will also prove advantageous as he spearheads the Company’s efforts into receiving funding through several possible financing avenues including the CHIPS Act, the Infrastructure Bill, and state funding, among others.

“As The Coretec Group grows, we require an experienced team, capable of enabling us to scale and conduct broader commercial activity,” said Matthew Kappers, Chief Executive Officer of The Coretec Group. “We are becoming far more operational than in years past and need a strong executive who can oversee that change. Hoffman is absolutely the person for the job. He has the strong analytical and communication skills needed for the role, as well as the managerial and leadership prowess to help guide this transition successfully.”

Hoffman joined The Coretec Group in May 2020, as its CFO, and will retain his duties within that role as he takes on the additional responsibilities of the COO. He is a graduate of Western Michigan University’s Haworth College of Business and is a certified public accountant in the State of Michigan.

“Working at The Coretec Group, on the forefront of technological innovation in transportation and energy, is rewarding and exciting, and this is still only the beginning,” said Hoffman. “In addition to our operations, we anticipate expansion of our team itself, making it critical to maintain a high level of management and execution. I look forward to working with our leadership team to make the most of this high growth opportunity.”

About The Coretec Group

The Coretec Group, Inc. is developing a portfolio of engineered silicon to improve energy-focused verticals, including electric vehicle and consumer batteries, solid-state lighting (LEDs), and semiconductors, as well as 3D volumetric displays and printable electronics. The Coretec Group serves the global technology markets in energy, electronics, semiconductor, solar, health, environment, and security.

For more information, please visit thecoretecgroup.com.

Follow The Coretec Group on:

Twitter – @CoretecGroupInc
LinkedIn – www.linkedin.com/company/24789881
YouTube – www.youtube.com/channel/UC1IA9C6PoPd1G4M7B9QiZPQ/featured

Forward-Looking Statements

The statements in this press release that relate to The Coretec Group’s expectations with regard to the future impact on the Company’s results from operations are forward-looking statements and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005578/en/


Permalink
https://www.aetoswire.com/en/news/1910202227875
Contacts
Corporate Contact:

The Coretec Group, Inc.
Lindsay McCarthy
info@thecoretecgroup.com
+1 (866) 916-0833

Media Contact:

Spencer Herrmann
FischTank PR
coretec@fischtankpr.com
+1 (518) 669-6818

Go Back

20 blog posts

Blog Search

Comments

There are currently no blog comments.